Recurrent Intracerebral Hemorrhage Often Strikes Close to Initial Site, Study Finds

For this purpose, the researchers conducted a pooled analysis of individual cohort studies from 2002 to 2021, focusing on hospital-based European cohorts. The study included patients who had experienced at least two clinically distinguishable small vessel disease–related intracerebral hemorrhage (ICH) events. Data analysis was carried out from December 2023 to December 2024.

Researchers examined ICH location and underlying small vessel disease type, with adjacent ICH (adjICH) as the primary outcome and time to recurrence as the secondary outcome. Multivariable regression analyses were performed, adjusting for factors such as ICH location, cerebral amyloid angiopathy, hypertension, and antihypertensive treatment.

The key findings of the study were as follows:

• The study included 733 patients with a median age of 72.4 years, of whom 47.2% were female.
• 1,616 ICH events were recorded, including 733 initial (index) and 883 recurrent events, with patients experiencing up to six recurrences.
• Over a median follow-up of 2.53 years, 46.4% of patients had adjacent ICH (adjICH), while 53.6% had remote ICH (remICH).
• Among recurrent cases, 476 were adjICH, and 407 were remICH.
• Lobar index ICH (aOR 2.08) and cerebral amyloid angiopathy (aOR 2.21) were linked to a higher risk of adjICH.
• Cerebellar index ICH was associated with lower odds of adjICH (aOR 0.25).
• The median time to recurrence was 1.25 years for adjICH and 2.21 years for remICH.
• Previous lobar or convexity subarachnoid hemorrhage, adjICH, and a higher number of prior ICH events were independently linked to a shorter time to recurrence.

The researchers found that early recurrence and characteristics of cerebral amyloid angiopathy were strongly associated with adjacent ICH. Their findings indicate that regional, tissue-based factors may contribute to recurrence, with spatial and temporal clustering suggesting localized vulnerabilities.

"By identifying and targeting these vasculopathic changes, our study highlights potential novel treatment approaches to reduce the risk of recurrent ICH," they concluded.

Reference:

Goeldlin MB, Fandler-Höfler S, Pezzini A, et al. Location and Timing of Recurrent, Nontraumatic Intracerebral Hemorrhage. JAMA Neurol. Published online March 03, 2025. doi:10.1001/jamaneurol.2025.0026